This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
3/16/2021
Ladies and gentlemen, thank you for standing by, and welcome to the Infinity Pharmaceuticals conference call to discuss the company's operations and full year 2020 financial results. My name is Victor, and I'll be your operator for today's call. At this time, all participant lines are in listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at Infinity's request. Now, I would like to introduce your host for today's call, Jane Kaufman. Please go ahead.
Thank you, Victor, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review of our full 2020 financial results. On the call with me today are Adeline Perkins, Chief Executive Officer, Larry Block, President, and Brian Schwartz, Consulting Chief Physician. We'll open up the call for Q&A following our remarks. The press release issued this afternoon details our results and is available on our website at infi.com. Please note that during this call we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies, and financial projections. Our actual results may differ materially from what we project today due to a number of important factors, including the considerations described in the risk factors section of our quarterly report, on Form 10-Q for the third quarter of 2020, and in other filings we make with the SEC. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events, or otherwise. Now, I would like to turn the call over to Adeline.
Thanks, Jane, and thank you to everyone for joining us today. The past four months have been transformative for big analysts at An Infinity, with two presentations of MERIO-1 data at the Society for Immunotherapy of Cancer meeting in November, two presentations at the San Antonio Breast Cancer Symposium in December of frontline triple negative breast cancer data from our MERIO-3 study, and second line and above, TNBC and ovarian cancer data from the ARC-II study conducted by our collaborator, Arcus Biosciences, and our most recent presentation last month of MERIO-275 data in second-line urothelial cancer at ASCO-GU, which together demonstrate the broad potential of aganalysib to improve upon diverse standard of care treatment regimens. We're thrilled that our foundational work in discovering and developing aganalysib a first-in-class macrophage reprogramming therapeutic candidate in solid tumors, has now translated through to clinical benefit across our program, driven by Aganalysed's unique and fundamental immune-modulating mechanism. On today's call, our Consultant Chief Physician, Dr. Brian Schwartz, will review the clinical and translational data from our recent Aganalysed presentations and discuss next steps for our program. But before that, I'd like to briefly summarize this encouraging data. First, data from MARIA-1, our Phase I 1B study in collaboration with Bristol-Myers Squibb, evaluating aganalysib in combination with Opivo in patients with advanced solid tumors, was presented at SISI. The data from this study reinforced the potential of aganalysib to overcome resistance to checkpoint inhibition in patients with melanoma and squamous cell cancer of the head and neck, who had progressed on a checkpoint inhibitor as their immediate prior therapy. Second, data from the TNBC cohort of Mario 3, our Phase II study in collaboration with Roche Genentech, and would clear evaluate in the combination of a Ganylisib with Ticentric and Abraxane as a frontline treatment in patients with TNBC, was presented at SABSI. The data showed an increase in the overall response rate and disease control rate versus the concentric anabraxane doublet therapy approved for the treatment of PD-L1 high frontline CNBC patients. Additionally, 100% of patients in this study achieved a reduction in tumor volume irrespective of PD-L1 status, and there was a 100% response rate in PD-L1 high patients. Third, data from our ARCIC collaboration, a phase 1b study evaluating aganalysib in a novel checkpoint inhibitor-free regimen that includes their dual-identifying receptor antagonist, endoxyl, in patients with relapsed refractory triple-negative breast cancer and ovarian cancer was also presented at SABSI. This data showed an increase in response rate with the addition of aganalysib to the novel doublet therapy in both indications. And finally, data from MARIO275, our randomized double-blind placebo-controlled stage 2 study in collaboration with BMS, in which we are evaluating aganalysib in combination with Opdivo in patients with advanced urothelial cancer, was presented at ASCO-GU last month. This data showed improvements in response rate, disease control rate, and progression-free survival, particularly in patients with low levels of PD-L1 expression who are known to not respond as well to checkpoint inhibitors. Across these studies, which include double and triple combinations in first, second, third, and beyond lines of therapy across multiple solid tumors, a clear signal is emerging that the addition of aganalysib improves upon standard of care regimens in diverse treatment settings and indications. These signs of efficacy are bolstered by our translational data, which show robust and highly consistent immune-modulating activity, providing clear mechanistic rationale for the ability of aganalysib to turn cold tumors hot and activate an immune response. This results in an upregulation of PD-L1, thus priming for checkpoint inhibition and improving responses in patients with some of the greatest unmet needs in oncology. The data has enabled us to begin mapping out a clear path forward with the analysis, including a potentially rapid path to approval in advanced urothelial cancer by focusing on the PD-L1 low population to address the significant unmet need for these patients. While the data we have generated suggests that aganalysib may provide benefit for both PD-L1 high and PD-L1 low patients, focusing on the PD-L1 low patient population in urothelial cancer provides a number of distinct advantages. First, there's a tremendous unmet need in PD-L1 low cancer patients with many checkpoint inhibitors not providing benefit for this population. evidenced by the fact that the approvals of Keytruda and Ticentric in frontline urothelial cancer are limited to PD-L1 high patients only. And even in cases where checkpoint inhibitors are approved for the entire intent-to-treat population, such as the Opdivo approval in second-line urothelial cancer, retrospective analyses have demonstrated that there's little to no benefit for the PD-L1 low patients. In Mario 275, we see that by adding aganalysib to Updivo, we increase the overall response rate in the PD-L1 low patients to a level that's equivalent to the response rate seen in the PD-L1 high patients with Updivo monotherapy in Checkmate 275. We had a similar success in bringing the disease control rate in PD-L1 low patients to a level above that what was achieved in PD-L1 high patients in Checkmate 275. enabling PD-L1 low patients to achieve the same level of benefit from immuno-oncology therapy as the PD-L1 high group. Furthermore, as a controlled trial, we were able to measure the difference in progression-free survival between the monotherapy and the ganylysin combination arm, which showed that PD-L1 low patients were 46% less likely to experience disease progression with the addition of a ganylysin. Importantly, Given the magnitude of the benefit seen with aganalysib in MARIO275 with a hazard ratio of 0.54, it should be possible to demonstrate its benefit in a registration-focused trial with a relatively few number of patients, such this trial can be smaller, faster, and less expensive to conduct. Our goal is to utilize aganalysib to extend the reach of immuno-oncology drugs to broader patient populations including those with low levels of PD-L1 expression who represent the largest patient population and have the greatest unmet need. From a strategic perspective, while we are initially focusing on the PD-L1 patients for the reasons I just highlighted, the data suggests aganalysib will also be of benefit more broadly beyond the PD-L1 low patients. This is because the immune-activating mechanism of aganalysib PD-L1 expression is increased regardless of whether patients are starting with low or high PD-L1 levels. So in the long term, the data suggests we'll ultimately provide broad benefit across patients and tumor types, but we're starting where we believe aganalysib can be approved most rapidly and cost-effectively in PD-L1 low patients. Before I turn the call over to Brian to provide a recap of the data and our next steps across our programs, I want to highlight that we're really thrilled with these data, which facilitated our recent $92 million public offering that leaves us very well positioned to continue the aggressive execution of our clinical development strategy. It's also important to note that aganalysib is the only macrophage-targeted therapeutic in clinical development focused on solid tumors. And given that we've retained full development and commercial rights for aganalysib, and have strong composition of matter patents through 2034, even prior to any patent term extension. Our unique, wholly-owned therapeutic candidate holds incredible promise for patients and value creation potential for shareholders. We are very grateful for the commitment and dedication of our employees, collaborators, partners, and especially our investigators and patients who have enabled this progress. And with that, I'll turn the call over to Brian.
You're reading a preview of the INFI Q4 2020 earnings call.
Free account.
